Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Lalli

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Cell Communication and Signaling : CCS|September 24, 2020
miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediatorsElisabetta Vergani, Matteo Dugo, Mara Cossa, et al.
Journal for Immunotherapy of Cancer|October 12, 2024
Cancer-associated foam cells hamper protective T cell immunity and favor tumor progression in human colon carcinogenesisElena Daveri, Barbara Vergani, Luca Lalli, et al.
The Journal of Clinical Investigation|September 28, 2018
Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanomaVeronica Huber, Viviana Vallacchi, Viktor Fleming, et al.
Molecular Genetics and Metabolism|June 18, 2026
Neuroradiological patterns and prognostic implications in type I Alexander diseaseYlenia Vaia, Filippo Arrigoni, Liat Ben Sira, et al.
Ebiomedicine|July 17, 2024
Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapySandro Pasquali, Viviana Vallacchi, Luca Lalli, et al.
Therapeutic Advances in Medical Oncology|December 22, 2023
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitorsEmma Zattarin, Luigi Mariani, Alice Menichetti, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 1, 2024
Sentinel node mapping in high-intermediate and high-risk endometrial cancer: Analysis of 5-year oncologic outcomesIlaria Cuccu, Francesco Raspagliesi, Mario Malzoni, et al.
Cancer Discovery|November 18, 2021
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with CancerClaudio Vernieri, Giovanni Fucà, Francesca Ligorio, et al.
NPJ Breast Cancer|April 17, 2023
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitorsEmma Zattarin, Daniele Presti, Luigi Mariani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2021
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET)Claudio Vernieri, Federico Nichetti, Luca Lalli, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Cell Communication and Signaling : CCS|September 24, 2020
miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediatorsElisabetta Vergani, Matteo Dugo, Mara Cossa, et al.
Journal for Immunotherapy of Cancer|October 12, 2024
Cancer-associated foam cells hamper protective T cell immunity and favor tumor progression in human colon carcinogenesisElena Daveri, Barbara Vergani, Luca Lalli, et al.
The Journal of Clinical Investigation|September 28, 2018
Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanomaVeronica Huber, Viviana Vallacchi, Viktor Fleming, et al.
Molecular Genetics and Metabolism|June 18, 2026
Neuroradiological patterns and prognostic implications in type I Alexander diseaseYlenia Vaia, Filippo Arrigoni, Liat Ben Sira, et al.
Ebiomedicine|July 17, 2024
Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapySandro Pasquali, Viviana Vallacchi, Luca Lalli, et al.
Therapeutic Advances in Medical Oncology|December 22, 2023
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitorsEmma Zattarin, Luigi Mariani, Alice Menichetti, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 1, 2024
Sentinel node mapping in high-intermediate and high-risk endometrial cancer: Analysis of 5-year oncologic outcomesIlaria Cuccu, Francesco Raspagliesi, Mario Malzoni, et al.
Cancer Discovery|November 18, 2021
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with CancerClaudio Vernieri, Giovanni Fucà, Francesca Ligorio, et al.
NPJ Breast Cancer|April 17, 2023
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitorsEmma Zattarin, Daniele Presti, Luigi Mariani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2021
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET)Claudio Vernieri, Federico Nichetti, Luca Lalli, et al.
Pageof 5